Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy.

Garg SK, Ott MJ, Mostofa AGM, Chen Z, Chen YA, Kroeger J, Cao B, Mailloux AW, Agrawal A, Schaible BJ, Sarnaik A, Weber JS, Berglund AE, Mulé JJ, Markowitz J.

Front Immunol. 2020 Feb 25;11:164. doi: 10.3389/fimmu.2020.00164. eCollection 2020.

2.

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.

Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ.

Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28.

PMID:
31462408
3.

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20.

PMID:
30713125
4.

OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms.

Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW.

Cytometry A. 2018 Oct;93(10):982-986. doi: 10.1002/cyto.a.23598. No abstract available.

5.

Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line.

Zhu G, Nemoto S, Mailloux AW, Perez-Villarroel P, Nakagawa R, Falahat R, Berglund AE, Mulé JJ.

Front Immunol. 2018 Jul 16;9:1609. doi: 10.3389/fimmu.2018.01609. eCollection 2018.

6.

Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy.

Yagawa Y, Robertson-Tessi M, Zhou SL, Anderson ARA, Mulé JJ, Mailloux AW.

Sci Rep. 2017 Nov 22;7(1):15996. doi: 10.1038/s41598-017-15924-2.

7.

Efficacy of ALK5 inhibition in myelofibrosis.

Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK.

JCI Insight. 2017 Apr 6;2(7):e90932. doi: 10.1172/jci.insight.90932.

8.

OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets.

Nemoto S, Mailloux AW, Kroeger J, Mulé JJ.

Cytometry A. 2016 May;89(5):427-9. doi: 10.1002/cyto.a.22808. Epub 2016 Feb 9. No abstract available.

9.

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK.

Haematologica. 2014 Jul;99(7):1176-83. doi: 10.3324/haematol.2012.083345. Epub 2014 Jan 31.

10.

Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP Jr, Epling-Burnette PK.

J Immunol. 2013 Oct 1;191(7):3578-93. doi: 10.4049/jimmunol.1203424. Epub 2013 Sep 6.

11.

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK.

Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30.

12.
13.

Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.

Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK.

J Immunol. 2012 Sep 15;189(6):3198-208. doi: 10.4049/jimmunol.1200602. Epub 2012 Aug 8.

14.

Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC.

Blood. 2012 Aug 2;120(5):1027-38. doi: 10.1182/blood-2011-11-394346. Epub 2012 Jun 12.

15.

Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.

Mailloux AW, Young MR.

Crit Rev Immunol. 2010;30(5):435-47. Review.

16.
17.

NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Mailloux AW, Young MR.

J Immunol. 2009 Mar 1;182(5):2753-65. doi: 10.4049/jimmunol.0801124.

18.
19.

GABAB receptor stimulation decreases amphetamine-induced behavior and neuropeptide gene expression in the striatum.

Zhou W, Mailloux AW, Jung BJ, Edmunds HS Jr, McGinty JF.

Brain Res. 2004 Apr 9;1004(1-2):18-28.

PMID:
15033416

Supplemental Content

Loading ...
Support Center